Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-24-01887 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Brian M Slomovitz und 29 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Medical Center, Miami Beach, FL. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, DNA Mismatch Repair, Endometrial Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Mismatch repair-deficient (dMMR) endometrial cancer (EC) is an inflamed phenotype with poor outcomes when meeting high-risk criteria and limited treatment options in the adjuvant setting. We report protocol-prespecified subgroup analysis of patients with dMMR tumors from the phase III ENGOT-en11/GOG-3053/KEYNOTE-B21 study (ClinicalTrials.gov identifier: NCT04634877 ) in newly diagnosed, high-risk EC after surgery with curative intent. Patients were randomly assigned to pembrolizumab 200 mg or placebo (six cycles) plus carboplatin-paclitaxel (four to six cycles) once every 3 weeks, then pembrolizumab 400 mg or placebo once every 6 weeks (six cycles), respectively. MMR status was a stratification factor. Patients received radiotherapy at investigator discretion. Investigator-assessed disease-free survival (DFS) was a primary end point. No formal hypothesis testing was performed for subgroup analysis. In the intention-to-treat population, 141 patients in the pembrolizumab arm and 140 in the placebo arm had dMMR tumors. At this interim analysis, hazard ratio for DFS favored pembrolizumab (0.31 [95% CI, 0.14 to 0.69]); median DFS was not reached in either group. Two-year DFS rates were 92.4% (95% CI, 84.4 to 96.4) and 80.2% (95% CI, 70.8 to 86.9), respectively. No new safety signals occurred. Longer-term follow-up of outcomes will be evaluated at final analysis. Preplanned subgroup analysis on the basis of the study's stratification factors suggests that pembrolizumab plus chemotherapy improves DFS and is clinically relevant for patients with dMMR tumors in the curative-intent setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mount Sinai Medical Center, Miami Beach, FL.
- GOG Foundation, Philadelphia, PA.
- Department of Gynecology, Obstetrics and Neonatology, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- Central and Eastern European Gynecologic Oncology Group (CEEGOG), Prague, Czech Republic.
- Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- Ankara University School of Medicine, Ankara, Turkey.
ORCID-Profile: Brian M Slomovitz, David Cibula, Floor Backes, Domenica Lorusso, Vanessa Samouëlian, Maria-Pilar Barretina-Ginesta, Christof Vulsteke, Chyong-Huey Lai, Bhavana Pothuri, Manuel Magallanes-Maciel, Valentina Guarneri, Martin Hruda, Laurence Gladieff, Toon Van Gorp
Zitieren
APA
Slomovitz, B. M., Cibula, D., Lv, W., Ortaç, F., Hietanen, S., Backes, F., Kikuchi, A., Lorusso, D., Dańska-Bidzińska, A., Samouëlian, V., Barretina-Ginesta, M. P., Vulsteke, C., Lai, C. H., Pothuri, B., Zhang, Y., Magallanes-Maciel, M., Amit, A., Guarneri, V., Zagouri, F., …, & Van Gorp, T. (2025). Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01887
Vancouver
Slomovitz BM, Cibula D, Lv W, Ortaç F, Hietanen S, Backes F, et al. Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-01887
BibTeX
@article{Slomovitz2025,
author = {Slomovitz, Brian M and Cibula, David and Lv, Weiguo and Ortaç, Fırat and Hietanen, Sakari and Backes, Floor and Kikuchi, Akira and Lorusso, Domenica and Dańska-Bidzińska, Anna and Samouëlian, Vanessa and Barretina-Ginesta, Maria-Pilar and Vulsteke, Christof and Lai, Chyong-Huey and Pothuri, Bhavana and Zhang, Yu and Magallanes-Maciel, Manuel and Amit, Amnon and Guarneri, Valentina and Zagouri, Flora and Bell, Maria and Welz, Julia and Eminowicz, Gemma and Hruda, Martin and Willmott, Lyndsay J and Lichfield, Jasmine and Wang, Wei and Orlowski, Robert and Aktan, Gursel and Gladieff, Laurence and Van Gorp, Toon},
title = {Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-24-01887}
}
EUVIMED